Pluri Inc. (TLV:PLUR)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
1,137.00
-33.00 (-2.82%)
Feb 20, 2026, 1:44 PM IDT
Market Cap114.69M +27.9%
Revenue (ttm)4.27M +97.5%
Net Income-83.33M
EPS-10.23
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume912
Average Volume8,334
Open1,110.00
Previous Close1,170.00
Day's Range1,110.00 - 1,170.00
52-Week Range922.90 - 2,345.00
Betan/a
RSI54.97
Earnings DateFeb 6, 2026

About Pluri

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 142
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol PLUR
Full Company Profile

Financial Performance

In fiscal year 2025, Pluri's revenue was $1.34 million, an increase of 309.82% compared to the previous year's $326,000. Losses were -$22.58 million, 8.11% more than in 2024.

Financial numbers in USD Financial Statements